Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014;10(1):224-31.
doi: 10.4161/hv.26311. Epub 2013 Sep 9.

Seroprevalence of hepatitis B and immune response to hepatitis B vaccination in Chinese college students mainly from the rural areas of western China and born before HBV vaccination integrated into expanded program of immunization

Xue-Yan Liao  1 , Zhen-Zuo Zhou  2 , Fu-Bang Wei  2 , Han-Ning Qin  2 , Yuan Ling  2 , Rong-Cheng Li  3 , Yan-Ping Li  3 , Yi Nong  3 , Kui-Xia Sun  1 , Jie Li  1 , Hui Zhuang  1
Affiliations

Seroprevalence of hepatitis B and immune response to hepatitis B vaccination in Chinese college students mainly from the rural areas of western China and born before HBV vaccination integrated into expanded program of immunization

Xue-Yan Liao et al. Hum Vaccin Immunother. 2014.

Abstract

The prevalence of hepatitis B surface antigen (HBsAg) in a population aged 15 y or older was high in China, but an immunization strategy for this population was unavailable. We investigated the seroprevalence of hepatitis B and immune response to HBV vaccine in Chinese college students (n=2040 participants), 11.1%, 80.8%, and 8.1% had confirmed, unknown and no HBV vaccination history, respectively. The seropositive rates for HBsAg, anti-HBs sole and anti-HBs plus anti-HBc were 12.6%, 25.7%, and 30.1%, respectively. The HBsAg seropositive rate was significantly lower in participants with confirmed HBV vaccination history than in those with unknown or no vaccination history (5.3%, 13.6%, and 12.6%, respectively, P=0.0019). The anti-HBs alone seropositive rate was significantly higher in participants with confirmed HBV vaccination history than in those with unknown or no vaccination history (37.6%, 25.3%, and 13.8%, respectively, P<0.0001). Participants negative for HBsAg, anti-HBs, and anti-HBc at baseline (n=600) were given three doses of recombinant HBV vaccine (GlaxoSmithKline) at month 0, 1, and 6. Robust immune response was elicited after two and three doses (seroprotective rate: 91.9% and 99.0%, respectively, and geometric mean concentration [GMC]: 95.8 and 742.6 IU/L, respectively). Fourteen months after the third dose, the anti-HBs seroprotective rate of the group remained more than 97%. The seroprotective rates and GMCs did not differ significantly by vaccination history. This study suggested that three doses of 20 μg HBV vaccine were needed for college students negative for HBsAg, anti-HBs, and anti-HBc to ensure high seroprotective rates and concentrations.

Keywords: college students; hepatitis B; hepatitis B vaccine; immune response; seroprevalence.

PubMed Disclaimer

Figures

None
Figure 1. Study flowchart.
None
Figure 2. Anti-HBs seroprotective rate after HB vaccination given at month 0, 1, and 6 among participants seronegative for HBsAg, anti-HBs, and anti-HBc at baseline.
None
Figure 3. Anti-HBs response after HB vaccination given at month 0, 1, and 6 among participants seropositive for anti-HBc alone at baseline.
See this image and copyright information in PMC

References

    1. World Health Organization. Department of Communicable Disease Surveillance and Response. Hepatitis B 2002; 2:1-76; http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/
    1. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, et al. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27:6550–7. doi: 10.1016/j.vaccine.2009.08.048. - DOI - PubMed
    1. Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev. 2006;28:126–35. doi: 10.1093/epirev/mxj010. - DOI - PubMed
    1. Menzies R, McIntyre P. Vaccine preventable diseases and vaccination policy for indigenous populations. Epidemiol Rev. 2006;28:71–80. doi: 10.1093/epirev/mxj005. - DOI - PubMed
    1. Van Damme P. Hepatitis B: vaccination programmes in Europe--an update. Vaccine. 2001;19:2375–9. doi: 10.1016/S0264-410X(00)00457-6. - DOI - PubMed

Publication types

Substances

LinkOut - more resources